Supervivencia Global en Segunda Línea de Liposarcomas: un objetivo alcanzado

Study 309 (LPS): Liposarcoma Overall Survival

In Liposarcoma population,

7.2 month improvement in median OS with eribulin

Chawla SP, et al. Presented at CTOS 2015 Annual Meeting, Salt Lake City, UT, November 4-7, 2015

Eribulin

Dacarbazine

Median (months)

15.6

8.4

HR (95% CI)

0.511 (0.346–0.753)

P-value

0.0006